Art Bioscience
Israel - RehovotBiotechnology
Focus: Art Bioscience is a publicly traded Israeli biotechnology company headquartered in Rehovot, focused on developing gene therapy treatments for Duchenne muscular dystrophy (DMD). The company operates as a specialized gene therapy player in a niche but high-value therapeutic area.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
3+3 this month
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Should You Work at Art Bioscience?
AI assessmentArt Bioscience presents a high-risk, high-reward opportunity for gene therapy specialists willing to bet on a pre-revenue, publicly traded DMD play with limited transparency into clinical progress and financial health.
Why Work Here
- Focused pipeline in DMD gene therapy, a well-defined orphan indication with significant unmet medical need and premium pricing potential
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Art Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.